STROMAL TUMORS
(GIST)
GIST is a rare cancer affecting the gastrointestinal (GI) system. In most cases, GISTs arise in the stomach or small intestine, but can form anywhere along the digestive tract. GISTs are most often driven by genetic mutations in the KIT tyrosine kinase receptor gene.
GIST can advance and spread to other parts of the body including the lungs and bone. Progression of GIST varies widely depending on the location, size, and aggressiveness of the tumor. In addition to surgery, GIST is often treated with KIT/ PDGFR⍺ tyrosine kinase inhibitors such as imatinib in the first line and sunitinib in the second line.
YOU’RE NOT ALONE
ON YOUR GIST JOURNEY.
GISTPathways.com is an online resource offering support, education, and information for those living with GIST and their caregivers.
Peak is a Phase 3 clinical trial evaluating bezuclastinib (CGT9486), a selective and potent KIT inhibitor, in combination with sunitinib vs. sunitinib alone, in people with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors (GIST) who have previously received imatinib.
FULLY ENROLLED
We were honored to partner with The Life Raft Group and GIST community to build this wonderful photo mosaic honoring those who have been impacted by GIST. The stories and images are truly inspiring. It’s incredible to see the impact we can have when we come together as a community to help build hope together!
About the Artist: Heather Poston started experimenting with watercolor 2 years ago creating cards for celebrations. When she learned about Mast Cell diseases and that a close friend was diagnosed with Systemic Mastocytosis, she created art to express her interpretation of the journey her friend experienced with the disease. This artwork expresses the relationship between mast cells and nature and illustrates how something so rare and life-threatening can also be beautiful.
COMMUNITY UPDATES & RESOURCES
Letter to the GIST Community – April 2026
New Drug Application (NDA) for bezuclastinib for patients with GIST accepted by FDA
Letter to the GIST Community – November 2025
Positive Peak Clinical Trial Top-Line Results
Letter to the GIST Community – September 2025
Cogent’s Expanded Access Program
Letter to the GIST Community – September 2024
Peak Clinical Trial Enrollment Complete
An Introduction to GIST
A resource for those newly diagnosed that provides general information about GIST including: diagnosis, treatment and management, questions to ask your provider and more.
Subscribe for Email Updates
Sign-up to receive email updates from Cogent about Gastrointestinal Stromal Tumors related news, including information about clinical trials and programs that Cogent offers or sponsors.
